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Abstract 
The S. cerevisiae RAD51 gene product exerts important functions in meiotic and mitotic recombination, as well as in the repair of 
DNA double-strand breaks. We have studied the expression of the human RAD51 (HsRAD51) gene in primary human peripheral blood 
lymphocytes (PBLs). The HsRAD51 mRNA level increased three fold in mitogen stimulated PBLs, with a peak in the late S phase. A 
five fold increase of HsRAD51 protein levels was observed in late G2. Specific inhibition of DNA synthesis with aphidicolin did not 
block the induction of the HsRAD51 protein, indicating that HsRAD51 expression is independent of DNA replication. In contrast, after 
inhibition of RNA synthesis with actinomycin D and protein synthesis with cycloheximide, the HsRAD51 protein level decreased rapidly. 
Taken together, these results indicate that the HsRAD51 gene is transcriptionally regulated in human PBLs, and exerts its function during 
the late S and G2 phases of the cell cycle. 
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1. Introduction 
Recombination i mammalian cells is used in the rear- 
rangement of the T-cell receptor and immunoglobulin genes 
in pre T- and B-cells, respectively, and probably in one of 
several DNA repair pathways as well [1,2]. In E. coli the 
main recombination protein is RecA, which exerts a dual 
function as a recombinase and as a controlling factor of the 
SOS response [3,4]. In S. cerevisiae there are four proteins 
with homology to RecA; DMC1, RAD51, RAD55 and 
RAD57. DMC1 is specifically expressed uring meiosis, 
whereas RAD51, RAD55 and RAD57 are needed during 
both meiosis and mitosis [5-9]. The latter belong to the 
RAD52 epistasi group, and have important functions in 
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recombination and repair of DNA double-strand breaks 
[10,11]. Data suggesting that members of the RAD52 
group act together in protein complexes have been re- 
ported [12-14]. Yeast cells with mutations in anyone of 
the ten or more genes in this group are sensitive to 
x-irradiation and other DNA damaging agents [11]. Ex- 
pression of the S. cerevisiae RAD51 gene is cell cycle 
regulated and inducible by DNA damaging agents [5-7]. 
The S. cerevisiae RAD51 protein is able to catalyse DNA 
strand-transfer [15,16], and can form the same type of 
nucleoprotein filaments with ssDNA and dsDNA as RecA 
[16,17]. 
Several mammalian homologues of the RAD51 in S. 
cerevisiae have been described [18,19]. The human RAD51 
(HsRAD51) protein forms helical nucleoprotein filaments 
on dsDNA with characteristics similar to those of the 
RecA and yeast RAD51 proteins, indicating that the hu- 
man protein is also a recombinase [20]. However, little is 
known about the expression of HsRAD51 in human cells. 
In this report we have studied the expression of HsRAD51 
during the cell cycle in primary human peripheral blood 
lymphocytes (PBLs). These cells are normally in the rest- 
ing GO phase, and after mitogen stimulation they enter a 
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synchronised cell cycle making them useful models for 
this type of study. 
2. Materials and methods 
2.1. Cells and culture conditions 
PBLs were obtained from blood cell concentrates of
healthy male blood donors and purified by centrifugation 
in Ficoll-Paque (Pharmacia) gradients. The cells were re- 
suspended in nutrient medium (NM), which is RPMI 1640 
(Gibco) containing 10% foetal calf serum, 10 i~g/ml 
streptomycin, 150 IU/ml benzyl penicillin and 20 mM 
L-glutamine. Cells designated 'unstimulated' were sampled 
from this cell suspension. Phytohaemaglutinin (PHA)- 
stimulated cultures were established in NM by the addition 
of 0.3% PHA (Wellcome) to the medium. The cells were 
kept at a density of 1. 106/ml at the time of PHA 
stimulation. 
PFI-285, a transformed T-lymphocyte cell line obtained 
from Dr. Anne-Lise Bcrresen (Norsk Radium Hospital, 
Oslo), was cultured as previously described [21]. PFI-285 
cells were arrested by serum starvation in reduced NM 
(serum content 0.5% for 50 h) before being resuspended in 
NM containing 10% foetal calf serum at a density of 
1 • 10 6 cells/ml. Normal doubling time for PFI-285 is 48 
h. 
2.2. RNA isolation, Northern blotting analysis 
ixg/ixl. Cycloheximide and actinomycin D (both from 
Sigma) were dissolved in ethanol, and added to the cell 
cultures at final concentrations of 100 ixg/ml and 5 
p~g/ml, respectively, atindicated time points. 
2.5. Cell extracts 
Extracts were prepared by lysing the cells in ice-cold 
sample buffer (50 mM HEPES, 500 mM NaC1, 0.05% 
Tween 20, 0,1% Triton X-100, 0,1 mM PMSF, 0.002 
mg/ml Leupeptin, 1 Ixg/ml Aprotinin, 1 Ixg/ml Pep- 
statin, 1 mM DTT). The extracts were sheared with a 20 
Gauge needle, and the protein concentration was measured 
with Bio Rad Protein assay kit II (Bio Rad) as described 
by the manufacturer. 
2.6. Primary antibodies 
HsRAD51 protein was expressed in E. coli, purified 
and used to produce rabbit polyclonal antibody. Preim- 
mune serum was taken prior to the immunisation. 
HsRAD51 protein (200 txg in complete Freund's adjuvant) 
was injected subcutaneously. Further immunisations (100 
Ixg in incomplete Freund's adjuvant) were repeated at 
2-wk intervals for 12 wk. Anti-PCNA (PC10) and anti-actin 
antibodies were obtained from St. Cruz Biotechnology and 
Amersham, respectively. Polyclonal PU101 antibody to 
human Uracil-DNA glycosylase (UNG 15) was courteously 
provided by Dr. Hans Krokan, University of Trondheim, 
Norway. 
Total RNA was prepared by acid guanidium thio- 
cyanate/phenol chloroform extraction [22], separated (30 
i~g from each cell fraction) on a 1.0% agarose gel contain- 
ing 6% formaldehyde, and transferred onto Qiabrane mem- 
branes (Qiagen) for hybridization as described [23]. A full 
length cDNA probe of the human RAD51 gene was used 
[25]. RNA content was normalized by rehybridization of
the filters with a $26 ribosomal protein probe [26]. (Primers 
and PCR conditions for isolation of the $26 cDNA were 
courteously provided by Dr Anton Platz, Radiumhemmet, 
Karolinska Hospital). Probes were labelled by random 
priming as described [24]. The hybridization signals were 
detected using a Fujix BAS 2000 phosphoimager system. 
2.3. Pulse labelling of DNA with [3H]thymidine 
2. 7. Western blotting 
Cell extract proteins (50 txg/lane) were resolved by 
SDS/PAGE, transferred to PVDF membrane (Amersham 
or Millipore) and probed with primary antibody (see above) 
followed by horseradish peroxidase sheep anti-mouse or 
donkey anti-rabbit IgG (Amersham), as described [27]. 
Antibody binding was detected by enhanced chemilumi- 
nescence (Amersham). The PVDF membranes were 
stripped to allow consecutive probing as suggested by the 
manufacturer. HsRAD51 protein expressed in and purified 
from E. coli was used as a positive control. Protein 
content of each lane was normalized by reprobing the 
filters with anti-actin antibody. The antibody-binding sig- 
nals were quantitated by densitometry. 
Portions of 1. 10 6 cells were removed and pulse la- 
belled with [3H]thymidine (1 ixCi/ml) for 30 min. Tri- 
chloroacetic acid (TCA)-precipitable radioactivity was de- 
termined by scintillation counting. 
2.4. Inhibitors 
Aphidicolin (Sigma) was dissolved in methanol and 
added to the cell culture at a final concentration of 2 
3. Results 
Initially, we studied the level of HsRAD51 mRNA in 
PHA-stimulated PBLs as the cells progressed through the 
first cell-cycle. HsRAD51 mRNA was almost undetectable 
in unstimulated G0-cells, but increased following PHA 
stimulation (Fig. 1). At 15 h, the level of mRNA was 
doubled with a further increase to three times the level of 
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Fig. 1. Relative changes inHsRAD51 mRNA levels in PBLs at different 
time points after PHA stimulation. The data were obtained by quantitating 
a Northern blot (not shown). RNA content was normalized by rehy- 
bridization with a $26 ribosomal protein probe. 
unstimulated cells by 40 h• The mRNA level had begun to 
decline by 48 h. The increase in HsRAD51 protein level 
followed the mRNA induction, but with delayed kinetics 
(Fig. 2). Proliferating Cell Nuclear Antigen, PCNA, a 
protein that is known to increase steadily through the cell 
cycle [28], increased in parallel to the HsRAD51 protein. 
As shown in Fig. 3, [3H]thymidine incorporation indicat- 
ing DNA synthesis peaked around 40 h, whereas both 
HsRAD51 and PCNA protein levels peaked around 48 h, a 
time point corresponding to late G2 in PBLs under the 
conditions used [29]. 
To study the possible connection between HsRAD51 
expression and DNA replication, PBLs were treated with 
aphidicolin which specifically blocks DNA synthesis. 
Aphidicolin was added at the time of PHA stimulation, and 
samples were taken at different ime points up to 65 h after 
stimulation. An untreated control culture was run in paral- 
lel, and pulse labelling with [3H]thymidine was performed 
to determine aphidicolin efficacy. Aphidicolin effectively 
stopped DNA replication, as no [3H]thymidine was incor- 
porated in aphidicolin treated cells (data not shown). How- 
ever, aphidicolin treatment had no effect on the mitogen 
stimulated increase in protein levels of HsRAD51 and 
0 22 41 48 63h 
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Fig. 2. Western blot showing HsRAD51 and PCNA protein levels in 
PBLs at different time points after PHA stimulation. The filters were 
reprobed with anti-actin antibody to control for loading differences. 
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Fig. 3. Relative changes inHsRAD51 (a) and PCNA (b) protein levels in 
human primary PBLs in relation to [3H]thymidine incorporation at differ- 
ent time points after PHA stimulation. The protein data were obtained by 
densitometry of the Western blots shown in Fig. 2. Protein content was 
normalized by reprobing the filters with anti-actin antibody. Triangle, 
[3H]thymidine incorporation; Square, HsRAD51 protein; Circle, PCNA 
protein. 
PCNA (Fig. 4). This result demonstrates that HsRAD51 
expression, like PCNA expression, is independent of DNA 
replication in mitogen stimulated PBLs. 
Inhibition studies were carried out to study whether the 
increase in the HsRAD51 protein level is due to transcrip- 
tional activation or a decrease in the turnover of the 
HsRAD51 protein• PBLs were treated either with actino- 
mycin D, which inhibits transcription, or cycloheximide, 
which inhibits protein synthesis, at different time points. 
The addition of actinomycin D 7 h after PHA stimulation 
completely abrogated the increase of HsRAD51 protein 
seen in the untreated control culture. Addition at 17 h 
decreased the induction substantially in comparison with 
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Fig. 4. Effect of treatment with aphidicolin on HsRAD5I and PCNA 
protein levels in PBLs at different ime-points after PHA stimulation. 
Aphidicolin was added at the time of PHA stimulation. The data were 
obtained by densitometry of Western blots (not shown). Protein content 
was normalized by reprobing the filters with anti-actin antibody, Squares, 
HsRAD51 protein; Circles, PCNA protein. Open symbols: without 
aphidicolin, Filled symbols: in the presence of aphidicolin. 
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Fig. 7. Relative changes in HsRAD51 protein levels in relation to 
[3H]thymidine incorporation at different ime-points after release of PFI- 
285 cells from serum starvation. The data were obtained by densitometry 
of Western blots (not shown). Protein content was normalized by reprob- 
ing the filters with anti-actin antibody. Triangle, [3H]thymidine incorpora- 
tion; Square, HsRAD51 protein. 
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Fig. 5. Western blot showing the effect of actinomycin D on HsRAD51 
protein levels in PBLs at different time-points after PHA stimulation. 
Actinomycin D was added either 7 or 17 h after PHA stimulation. The 
filters were reprobed with anti-actin antibody to control for loading 
differences. HsRAD51 protein levels in a control culture run in parallel is 
shown to the left. + indicates positive control (full length HsRAD51 
protein). 
Control Cycloheximide 
Oh 
ACT1N ~i l  . . . . . . . .  
+ 0 22 41 48 0 22 41 48 63h 
17h 30h 
RAD51 ~1111 ~ . ~,~ 
ACTIN 
0 22 41 48 63 0 22 41 48 63h 
Fig. 6. Western blot showing the effect of cycloheximide on HsRAD51 
protein levels in PBLs at different ime-points after PHA stimulation. 
Cycloheximide was added 0, 17 or 30 h after PHA stimulation. The filters 
were reprobed with anti-actin antibody to control for loading differences. 
HsRAD51 protein levels in a control culture run in parallel is shown to 
the left. + indicates positive control (full length HsRAD51 protein). 
Filters showing protein levels after cycloheximide treatment have been 
overexposed in order to exhibit he week signals at 0 h. 
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the concurrent control (Fig. 5). These results suggest that 
the HsRAD51 gene is transcriptionally regulated. In simi- 
lar experiments, addition of cycloheximide 0, 17 or 30 h 
after PHA stimulation caused a considerable reduction of  
the protein levels, as compared to the concurrent control at 
22 and 4! h, respectively (Fig. 6). Thus, the turnover time 
of the protein is l ikely to be less than 10 h. The rapid 
protein degradation further supports transcriptional regula- 
tion of  the HsRAD51 gene. 
It could not be excluded that the observed HsRAD51 
induction was due to the potent mitogenic effect of  PHA. 
Therefore, we studied the HsRAD51 expression in a trans- 
formed human T- lymphocyte cell line, PFI-285 [21], to 
confirm that the induction is really a cell cycle regulated 
phenomenon. The cells were arrested in the GO phase by 
serum starvation, and stimulated to enter the cell cycle by 
raising the serum concentration i the media. DNA replica- 
tion was monitored by [3H]thymidine incorporation, and 
HsRAD51 protein levels were measured at different time- 
points after release from the G0-stage. The [3H]thymidine 
incorporation increased gradually up to 72 h, and as in 
PBLs, the HsRAD51 protein expression increased in paral- 
lel with the [3H]thymidine incorporation (Fig. 7). This 
result supports our previous data indicating that the expres- 
sion of  the HsRAD51 protein is associated with the pro- 
gression through the cell cycle. 
4. Discussion 
We have studied the t ime-course of  the mRNA and 
protein expression of  HsRAD51 during the cell cycle in 
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primary human PBLs. The HsRAD51 mRNA level reached 
a maximal 3-fold increase (Fig. 1) at a time-point coincid- 
ing with the peak of the S-phase [29]. This is similar to the 
induction of RAD51 in synchronized S. cerevisiae cells, 
where the mRNA level peaks at the G1/S boundary [7]. 
The HsRAD51 protein level increased 5-fold, and the 
protein peak was slightly delayed compared to the mRNA 
peak. Both HsRAD51 and PCNA protein levels showed 
maximal induction at late G2 (Fig. 3). It has been shown 
previously that the cell-cycle regulated PCNA protein 
reaches its highest expression at the G2/M border in Molt 
4 cells [28]. 
The difference in time course of HsRAD51 expression 
between the PBLs (Figs. 3 and 4) and the PFI-285 cells 
(Fig. 7) is probably related to the conditions of cell cycle 
induction. In the PHA stimulated PBL culture the cells are 
synchronised uring the first cell cycle, whereas serum 
starved PFI-285 cells show ~ less synchronised response to 
mitogen stimulation. Nevertheless, in both cultures there 
was a relatively good correlation between [3H]thymidine 
incorporation and HsRAD51 levels, indicating that the 
HsRAD51 protein is accumulated uring the S and G2 
phases. 
The parallel increase of' [3H]thymidine incorporation 
and HsRAD51 protein level (Figs. 3 and 7) indicates that 
DNA replication and HsRAD51 induction could be coreg- 
ulated. However, specific inhibition of DNA synthesis 
with aphidicolin showed that both HsRAD51 and PCNA 
protein levels increased irrespective of a total block of the 
S phase (Fig. 4). The PCNA induction is consistent with 
earlier findings in aphidicolin-treated mouse fibroblasts 
[30]. The same response has also been observed with 
regard to the cell-cycle regulated protein UDG after 
aphidicolin-treatment of human fibroblasts [31 ] and PBLs 
(J.F. unpublished results). Apparently, blocking DNA 
replication is insufficient to prevent the expression of some 
cell cycle regulated proteins, e.g. HsRAD51, PCNA and 
UDG, in cells which are stimulated to enter the cell cycle. 
In principle, the obsepled increase in the level of 
HsRAD51 could be due to an increased protein synthesis 
or a change in protein stability. The inhibition experiments 
showed that both RNA and protein synthesis were required 
for the HsRAD51 induction. When transcription was 
blocked by treatment with actinomycin D, HsRAD51 pro- 
tein levels decreased subs;tantially (Fig. 5). Moreover, 
HsRAD51 protein degradation was rapid, since inhibition 
of protein synthesis by treatment with cycloheximide r - 
duced the HsRAD51 protein to almost undetectable l vels 
(Fig. 6). Taken together, these results strongly suggest that 
the HsRAD51 gene is transcriptionally regulated. 
Given its function in yeast [16,17] recombinational re- 
pair is the most plausible role for HsRAD51 in PBLs. In S. 
cerevisiae, repair using intrachromosomal recombination 
between sister chromatids in G2 is preferred to interchro- 
mosomal recombination between homologous chromatids 
[32]. Interchromosomal recombination is also suppressed 
in human cells [33]. One could therefore speculate that 
HsRAD51 participates in intrachromosomal recombina- 
tional repair between sister chromatids during the S and 
G2 phases. This would be consistent with its induction 
following mitogen stimulation in PBLs, and its transcrip- 
tional regulation during the cell cycle, as demonstrated in 
the present study. 
Acknowledgements 
We thank The Swedish Board for Animal Protection, 
The Swedish Radiation Protection Institute, The Swedish 
Cancer Society, Magnus Bergvall Foundation, King Gustaf 
V:s Jubilee Fund, Foundation Lars Hiertas Minne, Alex 
and Eva WallstriAm foundation, and Karolinska Institutet 
for financial support. We would also like to thank Profes- 
sor Bo Lambert for fruitful discussions and PhD Derek 
Tobin for linguistic help. 
References 
[1] Kaufmann, W.K. (1989). Carcinogenesis 10, 1-11. 
[2] Naegeli, H. 1994. BioEssays 16, 557-564. 
[3] Roca, A.I. and Cox, M.M. (1990) Crit. Rev. Biochem. Mol. Biol. 
25, 415-456. 
[4] Cox, M.M. (1993) Bioessays 15, 617-623. 
[5] Shinohara, A., Ogawa, H. and Ogawa, T. (1992) Cell 69, 457-470. 
[6] Aboussekhra, A., Chanet, R., Adjiri, A. and Fabre, F. (1992) Mol. 
Cell. Biol. 12, 3224-3234. 
[7] Basile, G., Aker, M. and Mortimer, R.K. (1992) Mol. Cell. Biol. 12, 
3235-3246. 
[8] Bishop, D.K., Park, D., Xu, L. and Kleckner, N. (1992) Cell 69, 
439-456. 
[9] Lovett, S.T. (1994) Gene 142, 103-106. 
[10] Game, J.C. (1983) in Yeast Genetics: Fundamental nd Applied 
Aspects (Spencer J.F.T., Spencer D. and Smith A.R.W., eds.), pp. 
109-137, Springer Verlag, New York. 
[11] Game, J.C. (1993) Sem. Cancer Biol. 4, 73-83. 
[12] Johzuka, K. and Ogawa, H. (1995) Genetics 139, 1521-1532. 
[13] Hays, S.L., Firmenich, A.A. and Berg, P. (1995) Proc. Natl. Acad. 
Sci. 92, 6925-6929. 
[14] Johnson, R.D. and Symington, LS. (1995) Mol. Cell. Biol. 15, 
4843-4850. 
[15] Sung, P. (1994) Science 265, 1241-1243. 
[16] Sung, P. and Robberson, D.L. (1995) Cell 82, 453-461. 
[17] Ogawa, T., Yu, X., Shinohara, A. and Egelman, E.H. (1993) Science 
259, 1896-1899. 
[18] Yoshimura, Y., Morita, T., Yamamoto, A. and Matsushira, A. 
(1993) Nucl. Acids Res. 21, 1665. 
[19] Shinohara, A., Ogawa, H., Matsuda, Y., Ushio, N., Ikeo, K. and 
Ogawa, T. (1993) Nature Genet. 4, 239-243. 
[20] Benson, F.E., Stasiak, A. and West, S.C. (1994) EMBO J. 13, 
5764-5771. 
[21] Helgestad, J., Pettersen, R., Storm-Mathisen, I., Schjerven, L., Ul- 
rich, K., Smeland, E. B., Egeland, T., Sorskaard, D., Brogger, A. 
and Hovig, T. (1990) Eur. J. Haematol. 44, 9-17. 
[22] Farrell Jr., R.E., (1993) RNA methodologies: A laboratory guide for 
isolation and characterization. Academic Press, New York. 
[23] Ausubel, F.M., Brent, R., Kingston, R.E., Seidman, J. G., Smith, 
236 J. Flygare et aL / Biochimica et Biophysica Acta 1312 (1996) 231-236 
J.A. and Struhl, K., eds. Current Protocols in Molecular Biology. 
John Wiley and Sons, New York. 
[24] Feinberg, A.P. and Vogelstein, B. (1984) Anal. Biochem. 137, 
266-267. 
[25] Hellgren, D., Sahl6n, S., Ljungqvist, S. and Kenne, K. (1994) 
Human Genet. 94, 705-707. 
[26] Vincent, S.L.M. and Fort, P. (1993) Nucl. Acids Res. 21, 1498. 
[27] Harlow, E. and Lane, D. (1988) Antibodies; a laboratory manual., 
Cold Spring Harbor Laboratory. 
[28] Zeng, X-R., Hao, H., Jiang, Y. and Lee, M.Y.W.T. (1994) J. Biol. 
Chem. 269, 24027-24033. 
[29] Steen, A.-M., Sahl6n, S. and Lambert, B. (1991) Biochim. Biophys. 
Acta 1088, 77-85. 
[30] Bravo, R. (1986) Exp. Cell. Res. 163, 287-293. 
[31] Slupphaug, G., Olsen, L.C., Helland, D., Aasland, R. and Krokan, 
H.E. (1991) Nucl. Acids Res. 19, 5131-5137. 
[32] Kadyk, L.C. and Hartwell, L.H. (1992) Genetics 132, 387-402. 
[33] Shulman, M.J., Collins, C., Connor, A., Read, L.R., Baker, M.D. 
(1995) EMBO J. 14, 4102-4107. 
